UNSPSC 51112402: Dacarbazine

This classification denotes a triazene compound with the molecular formula C6H10N6O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7GR28W0FJI, chemically known as 5-(3,3-dimethyltriaz-1-en-1-yl)-1h-imidazole-4-carboxamide but more generally known as dacarbazine, which bears US NIH Compound Identifier 5281007. European Medicines Agency schedules Dacarbazine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06882MIG.

UNSPSC 51112402 Dacarbazine is a Commodity code covering procurement of the chemotherapy drug dacarbazine, used primarily in cancer treatment regimens. State and local governments purchase dacarbazine through health agencies, correctional departments, and public hospital systems to support inpatient and outpatient oncology programs, emergency departments, and specialty care clinics. Issuing bodies include state health and human services departments, county health systems, municipal hospitals, and state correctional agencies. The procurement mix spans direct pharmaceutical purchases, group purchasing organization (GPO) contracts, and pharmacy benefit manager (PBM) arrangements negotiated at the state or regional level to manage costs and ensure consistent supply across public healthcare networks.

The Texas Health and Human Services Commission posted Request for Information (RFI) HHS0017013 on April 3, 2026, to explore direct-to-manufacturer prescription programs that would establish relationships between the state's pharmacy benefit program and pharmaceutical manufacturers outside of traditional PBM and GPO channels. The RFI seeks vendor capabilities for direct contracting with self-insured employee health plans and state agencies, with emphasis on negotiated net pricing models and value-based agreements. This represents exploratory activity rather than a binding procurement commitment; the state plans to issue a formal Request for Proposal (RFP) after gathering market intelligence on available solutions and vendor experience with direct contracting in government sectors. No award value, budget allocation, or final response deadline has been published as of the RFI stage.